Evidence mapPaperPMID 39167675Full record

ReviewArteriosclerosis, thrombosis, and vascular biology2024

Inflammation and Atherosclerosis: Prospects for Clinical Trials.

Hafid Ait-Oufella, Peter Libby

Abstract readReview
In one paragraph

Review in Arteriosclerosis, thrombosis, and vascular biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Navigating immunity to predict cardiovascular risk.European journal of preventive cardiology · 2026
    Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Aqueous Extract ofNutrients · 2025
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Role of Inflammatory and Proresolving Mediators in Endothelial Dysfunction.Basic & clinical pharmacology & toxicology · 2025
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hafid Ait-OufellaUniversité Paris Cité, INSERM U970, Paris Cardiovascular Research Center (H.A.-O.), Sorbonne Université, France.ORCID 0000-0002-2955-0183
Peter LibbyDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (P.L.).ORCID 0000-0002-1502-502X

Funding

Role of group 2 innate lymphoid cells in myocardial infarctionR01HL157073 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · 2023 to 2025
$2.0M
Role of ILC2 and eosinophils in abdominal aortic aneurysmR01HL151627 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Peter Libby · 2022 to 2024
$2.0M
Role of eosinophil cationic proteins in cardiac hypertrophyR01HL166538 · BRIGHAM AND WOMEN'S HOSPITAL · 2025 to 2025
$714k
Mechanisms and Modulation of Accelerated Atherosclerosis in Clonal HematopoiesisR01HL163099 · BRIGHAM AND WOMEN'S HOSPITAL · 2025 to 2025
$650k
NHLBI NIH HHS R01 HL134892NHLBI NIH HHS R01 HL151627NHLBI NIH HHS R01 HL157073NHLBI NIH HHS R01 HL163099NHLBI NIH HHS R01 HL166538NIA NIH HHS R01 AG063839
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AtherosclerosisClinical Trials as TopicInflammationAnimalsAnti-Inflammatory AgentsHumansInflammation MediatorsAnti-Inflammatory AgentsInflammation Mediatorscardiovascular diseasescytokinesendothelial cellsimmunity, innateplaque, atherosclerotic

Identifiers

PMID39167675
PMCPMC11343092

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.